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Dosage formsAbstract A kinetic spectrophotometric method for accurate and sensitive determination of gemi-
ﬂoxacin (GMFX) and gatiﬂoxacin (GTFX) has been described. The method is based on the reac-
tion of the studied drugs with potassium permanganate in the presence of sodium hydroxide to form
a water-soluble green product which shows maximum absorbance at 604 nm. The determination of
GMFX and GTFX drugs by rate constant, ﬁxed-concentration, and ﬁxed time methods was feasi-
ble with the calibration equations obtained but the ﬁxed time method had been found to be more
applicable. The concentration of the selected drugs is calculated using the calibration equation for
the ﬁxed time method. The absorbance–concentration plot is linear over the range of 4–36 lg mL1
and 4–40 lg mL1 with correlation coefﬁcient of 0.9998 and 0.9991, for GMFX and GTFX, respec-
tively. The molar absorptivity, Sandell sensitivity, detection and quantiﬁcation limits were also cal-
culated. The different experimental parameters affecting the development and stability of the color
were carefully studied and optimized. The intra- and inter-day RSD values indicated the ruggedness
of the method. The proposed method has been successfully applied to pharmaceutical formulations
of each drug. Statistical comparison of the results with a well established reported method showed
excellent agreement and proved that there is no signiﬁcant difference in the accuracy and precision.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fluoroquinolones, as a group, have shown excellent activity
against the most frequently occurring gram-positive and -neg-
ative ocular pathogens [1,2,3,4,5]. Earlier generation ﬂuoro-
quinolones, such as ciproﬂoxacin and oﬂoxacin, have
been used widely to treat various pathogenic conditions.
Figure 1 Chemical structure of (a) gemiﬂoxacin and (b)
gatiﬂoxacin.
spectrophotometric determination of GMFX and GTFX S59However, the development of a resistant strain against these
ﬂuoroquinolones has been reported [6,7]. Gemiﬂoxacin and
gatiﬂoxacin are fourth-generation ﬂuoroquinolones, possess
an improved antibacterial spectrum, particularly against resis-
tant staphylococcus and streptococcus pathogens, compared
with older ﬂuoroquinolones [8,9].
Gemiﬂoxacin (GMFX) (R,S)-7(3-aminomethyl-4-syn-
methoxyimino-1-pyrrolidinyl)-1-cyclopropyl-6-ﬂuro-1, 4 dihy-
dro-4-oxo-1, 2 naphthyridine-3-carboxylic acid (Fig. 1a) [10].
Gemiﬂoxacin is an antibacterial compound with enhanced
afﬁnity for bacterial topoisomerase IV and is being used for
the treatment of respiratory and urinary tract infections. The
compound has a broad spectrum of activity against gram-po-
sitive and gram-negative bacteria. Gemiﬂoxacin mesylate is
not ofﬁcial in any pharmacopoeia.
Literature survey revealed that few analytical methods have
been reported for the estimation of GMFX in pharmaceutical
preparations or human plasma by visible spectrophotometry
[11,12], capillary electrophoresis [13], high performance liquid
chromatography–tandem mass spectrometry [14,15], and
microchip electrophoresis [16]. These methods were related
with some major drawbacks such as having inadequate sensi-
tivity, being time-consuming, tedious, and dedicated to sophis-
ticated and requiring expensive instruments.
Gatiﬂoxacin (GTFX) (1-cyclopropyl-6-ﬂuoro-1,4-dihydro-8-
methoxyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic
acid), (Fig. 1b) [17]. It is widely used in the treatment of urinary
tract infection, acute bacterial sinusitis, community acquired pneu-
monia, and acute bacterial exacerbation of chronic bronchitis [18].
Gatiﬂoxacin is an antibacterial drug having selective antimicrobial
activity against streptococcus pneumoniae and penicillin-resistant
pneumococci. It is also active against anaerobic pathogen, bacte-
roides fragilis, andmouthanaerobes [19]. It is available in the tablet
form and not ofﬁcial in any pharmacopoeia.Several techniques have been proposed for the quantiﬁca-
tion of GTFX in pure, pharmaceutical dosage forms and in
biological ﬂuids by titrimetry (Marona et al., 2003), voltamme-
try [20,21], chromatography [22,23,24,25,26,27], capillary elec-
trophoresis [28], atomic absorption spectrometry [29],
chemiluminescence [30], ﬂuorimetry, [31]; and [32] and spectro-
photometry [29,33,34,35,36]. The titrimetry is insensitive and
time consuming. The voltammetric, chromatographic, electro-
phoretic, atomic absorption spectrometric and chemilumino-
metric methods utilized dedicated and/or expensive
instruments that are not available in most quality control lab-
oratories’ analytical technique. Spectrophotometry is consid-
ered the most convenient analytical technique, because of its
inherent simplicity, low cost, and wide availability in most
quality control laboratories [37]. However, few spectrophoto-
metric methods were reported for the determination of GTFX
in its pharmaceutical dosage forms [29,33,34,35,36]. These
methods were associated with some major drawbacks such as
decreased selectivity due to measurement in ultraviolet region,
[33] and/or decreased simplicity of the assay procedure e.g. te-
dious precipitation, [29] or liquid–liquid extraction steps are
based on the formation of ion-pair complex [36].
The kinetic spectrophotometric method offers an easy, less
time consuming, sensitive analysis, by using simple and avail-
able reagents, which are able to be used for routine determina-
tions of drug substances. Therefore kinetic spectrophotometric
analysis is one of the major interests of analytical pharmacy.
This work represents the ﬁrst attempt at assaying gemiﬂoxacin
(GMFX) and gatiﬂoxacin (GTFX) in pharmaceutical prepara-
tions by the use of the kinetic spectrophotometric method. The
method is based on oxidizing the drugs with alkaline potas-
sium permanganate. The reaction is followed up spectrophoto-
metrically and the rate of change of absorbance at 604 nm is
measured. The ﬁxed time method is adopted after full investi-
gation and understanding of the kinetics of the reaction. The
proposed method is simple, accurate and sensitive.2. Experimental
2.1. Apparatus
All the absorbance spectral measurements were made using
spectroscan 80 D double-beam UV/Vis spectrophotometer
(Biotech Engineering Ltd., UK), with a wavelength range of
190–1100 nm, spectral bandwidth 2.0 nm, with 10 mm
matched quartz cells. A water bath shaker was used to control
the heating temperature for color development.
2.2. Reagents and solutions
All chemicals and reagents used were of analytical grade. High
purity double distilled water was used throughout.
i. Standard stock solutions of GMFX andGTFX containing
200 lg mL1 were prepared separately in distilled water.
GMFXandGTFXwere kindly supplied from the Egyptian
International Pharmaceutical Industries Company (EIPI-
CO), Egypt. Samples of adrenergic blocker drugs were gen-
erously supplied by their respectivemanufacturers andwere
used without further puriﬁcation. The stock and working
standard solutions must be freshly prepared.
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Figure 2 Absorption spectrum of GMFX (36 lg mL1) after
reaction with KMnO4 (1 · 103 M): (a) manganate ions and (b)
reagent blank.
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Figure 3 Effect of the volume of 5 · 103 M KMnO4 on the
reaction of GMFX (36 lg mL1) and GTFX (40 lg mL1) with
alkaline potassium permanganate. The reactions were carried out
at room temperature (25 ± 2 C).
S60 A.M. El-Didamony, M.O. Abo-Elsoadii. Commercial dosage forms of GMFX (320 mg/tablet
Floxgurad, product of Al-Debeiky Pharma, Al-Obour
City, Egypt) and GTFX (Tymer, sterile ophthalmic
solution 0.3% produced by JamJoom Pharmaceuticals,
Jeddah, Saudi Arabia).
iii. Potassium manganate (Merck, Germany), 5 · 103 M
aqueous solutions, should be freshly prepared and its
molarity was checked titrimetrically.
iv. NaOH (BDH, UK), 1.0 M aqueous solution was pre-
pared by dissolving 4.0 g of the chemical in 100 mL of
water.
2.3. General recommended procedure
Accurate volumes of GMFX or GTFX working solution over
the concentration range of 4–36 lg mL1 and 4–40 lg mL1,
respectively were transferred into a series of 10 mL standard
ﬂasks. To each ﬂask 1.5 mL of 1.0 M sodium hydroxide fol-
lowed by 2.0 mL of 5 · 103 M potassium permanganate was
added. Complete to volume with water and mix well. After
mixing, the reaction mixture was transferred to a thermostati-
cally controlled water bath adjusted to 70 ± 2 C or
50 ± 2 C, at ﬁxed time of 15 min for GMFX and GTFX,
respectively. Cool and then, measure the absorbance of solu-
tions at 604 nm against reagent blank treated similarly. Con-
struct the calibration graph by plotting the ﬁnal
concentration of the drug against the absorbance values, mea-
sured at a ﬁxed time of 15 min. Alternatively, derive the corre-
sponding regression equation.
2.4. Procedures for pharmaceutical formulations
2.4.1. Procedure for the tablets
Ten tablets of ﬂoxguard each containing 320 mg of GMFX
were crushed, powdered, weighed out and the average weight
of one tablet was determined. An accurately weighed portion,
equivalent to 20 mg was dissolved in about 10 mL of distilled
water and any remaining residue was removed by ﬁltration.
The ﬁltered solution was then transferred into a 100 mL cali-
brated ﬂask and diluted to 100 mL with water. The nominal
content of the tablet was assayed from the calibration curve.
2.4.2. Procedure for eye drops
The contents of ﬁve tymer samples (each 1.0 mL contains 3 mg
of GTFX) were mixed. A volume equivalent to 20 mg of
GTFX was transferred to a 100 mL volumetric ﬂask and made
up to the mark with water. Suitable dilution was made to ﬁt
the applicable concentration range and the above described
procedures were followed. The nominal content of the bottles
was calculated either from calibration graph or using the
regression equation.
3. Results and discussion
3.1. Optimization of parameters
The absorption spectrum of aqueous potassium permanganate
solution in alkaline medium exhibited an absorption band at
530 nm. The additions of any of the studied drugs to this solu-tion produce a new characteristic band at 604 nm (Fig. 2). This
band is due to the formation of manganate ion, which resulted
from the oxidation of GMFX by potassium permanganate in
alkaline medium. The intensity of the color increases with
time; therefore a kinetically based method was developed for
the determination of GMFX and GTFX in their pharmaceuti-
cal formulations. The various experimental factors affecting
the development and stability of the reaction product were
studied and optimized. Such factors which were changed indi-
vidually, include concentration of the reagents (KMnO4 and
NaOH), order of addition of reagents, temperature, time of
heating and buffer solutions.
3.1.1. Effect of KMnO4 concentration
Potassium permanganate oxidizes GMFX and GTFX in the
presence of sodium hydroxide to form the green product
resulting from the reduction of permanganate to manganate.
Different concentrations of potassium permanganate from
1 · 104 to 1.25 · 103 M were studied. The absorbance at
604 nm was measured at a ﬁxed time of 15 min. The reaction
increased substantially with increasing the concentration of
KMnO4 (Fig. 3). Maximum absorbance was obtained when
2.0 mL of KMnO4 solution was used (the concentration in
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Figure 5 Effect of time on the reaction of GMFX (36 lg mL1)
and GTFX (40 lg mL1) with alkaline potassium permanganate.
The reactions were carried out at room temperature (25 ± 2 C).
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Figure 6 Effect of temperature on the reaction of GMFX
(36 lg mL1) and GTFX (40 lg mL1) with alkaline potassium
permanganate.
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spectrophotometric determination of GMFX and GTFX S61the ﬁnal assay solution was 1.0 · 103 M). Further increase in
the concentration had no effect on the reaction.
3.1.2. Effect of NaOH concentration
NaOH concentration on the reaction rate was studied using
0.2–3.0 mL of 1.0 M NaOH. It was found that increasing the
volume of 1.0 M NaOH, would increase the absorbance of
the reaction product up to 1.0 mL. It was also observed that
there was no signiﬁcant difference in the absorbance of reac-
tant solutions at NaOH concentrations above 1.0 mL, while
decreasing NaOH concentration resulted in lower absorbance
values. Therefore, 1.5 mL of 1.0 M NaOH was found to be
the most suitable concentration for maximum absorbance
(Fig. 4). The effect of different Na salt buffers, particularly
acetate, borate, carbonate, oxalate and phosphate, was investi-
gated. No effect was observed when 0.01 M of these buffers
was added to a solution.
3.1.3. Effect of time
To study the effect of time, a ﬁxed concentration of the studied
drugs (36 lg mL1) was made to react with 2.0 mL of
5 · 103 M KMnO4 solution; absorbance readings were re-
corded at different times in the range of 2.0–40 min. The oxi-
dation reaction was completed in 35 min and the color was
stable up to 60 min in the presence of the reaction product(s)
(Fig. 5).
3.1.4. Effect of temperature
Preliminary test proved that a complete color formation was
achieved by heating the resulting solution in a thermostati-
cally-controlled water bath. Different temperature settings
were used with constant heating time. Increasing temperature
of the water bath was found to produce a proportional in-
crease in absorbance (Fig. 6). So, trials have been done to carry
out the reaction at higher temperatures but unwanted chemical
changes e.g. precipitation of manganese (II) dioxide might oc-
cur. To avoid this and for the sake of good results, the opti-
mum temperature of 70 ± 2 C and 50 ± 2 C was selected
for the determination of GMFX and GTFX, respectively.
The time of heating is an essential part of the experiment. Dif-
ferent time intervals were tested to ascertain the time after
which the solution attains its highest absorbance. It was found
that heating for 15 min gave the highest absorbance readings0.4
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Figure 4 Effect of the volume of 1.0 M NaOH on the reaction of
GMFX (36 lg mL1) and GTFX (40 lg mL1) with alkaline
potassium permanganate. The reactions were carried out at room
temperature (25 ± 2 C).
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Figure 7 Effect of heating time on the reaction of GMFX
(36 lg mL1) and GTFX (40 lg mL1) with alkaline potassium
permanganate.for each drug. Excessive heating time did not produce a signif-
icant increase in absorbance readings (Fig. 7).
3.1.5. Order of addition
The experimental parameters were ﬁxed, and further experi-
ments were performed to test the inﬂuence of the order of
the addition of reactants. It was found that the order (KMnO4,
NaOH and drug), results in maximum absorbance. Addition
S62 A.M. El-Didamony, M.O. Abo-Elsoadorders, other than those described in the procedure, gave lower
results.
3.1.6. Stoichiometric ratio
The stoichiometric ratio between studied drugs and potassium
permanganate was determined by the limiting logarithmic
method, [38] by performing two sets of experiments. In the ﬁrst
set, the concentration of drug was varied keeping a constant
concentration of KMnO4. In the second set of experiment,
concentration of drug was kept constant while varying the con-
centration of KMnO4. The logarithm of the absorbance was
plotted against the logarithm of the respective varied concen-
tration of drug or KMnO4 (Figs. 8 and 9). The slopes of the-1.4
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Figure 8 Limiting logarithmic plots for the molar ratio: (A) log
A vs. log [KMnO4], (B) log A vs. log [GMFX].
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Figure 9 Limiting logarithmic plots for the molar ratio: (A) log
A vs. log [KMnO4]; (B) log A vs. log [GTFX].
Table 1 Relation between reaction rates and concentrations.
Drug log DA/Dt log [drug] Regression equati
GMFX 3.041 4.387 log DA/Dt= 0.2
2.886 4.289
2.762 4.211
2.674 4.143
2.638 4.086
3.380 4.371
3.100 4.274
GTFX 2.951 4.195 log DA/Dt= 0.7
2.848 4.128
2.758 4.070two straight lines were calculated and found to be unity in each
case. Thus, the stoichiometric ratio between each drug and
potassium permanganate was found to be 1:1.
3.2. Evaluation of the kinetic methods
The quantitative determination of GMFX and GTFX under
the optimized experimental conditions outlined above would
result in a pseudo-ﬁrst order reaction with respect to their con-
centration where, KMnO4 concentration was at least 30 times
the concentration of each drug, and NaOH concentration was
at least 600 times the initial concentration of each drug. How-
ever, the rates will be directly proportional to drug concentra-
tion in a pseudo-ﬁrst order rate equation as follows:
Rate ¼ K0 þ ½Cn ð1Þ
Eq. (1) was the basis for several experiments, which were car-
ried out to obtain drug concentration. The rate constant, ﬁxed-
concentration, and ﬁxed time methods [39,40] were tried and
the most suitable analytical method was selected taking into
account the applicability, the sensitivity, the correlation coefﬁ-
cient (r), and the intercept. Taking logarithms of rates and con-
centrations (Table 1), the above equation becomes:
logK ¼ logDA=Dt ¼ log k0 þ n logC ð2Þ
where A is the absorbance, t is the time in seconds and K is the
pseudo-ﬁrst order rate constant. Regression of log (K) versus
log [C] gave the regression equations:
log K ¼ log DA=Dt ¼ 0:2524þ 0:6389 log C;
r ¼ 0:9971 for GMFX
log K ¼ log DA=Dt ¼ 0:7526þ 0:8835 log C;
r ¼ 0:9997 for GTFX
A straight line with slope values of (n  1) was obtained con-
ﬁrming that the reaction was ﬁrst order.
3.2.1. Fixed-time method
Reaction rates were determined for different concentrations of
the investigated drugs. At a preselected ﬁxed time, which was
accurately determined, the absorbance was measured. Calibra-
tion graph of absorbance versus initial concentration of drugs
was established at ﬁxed time of 2, 5, 7, 10, 13, 15, 20, 25 and
30 min (Figs. 10 and 11) with the regression equation assem-
bled in Table 2. It is clear that the slope increases with time
and the most acceptable values of the correlation coefﬁcient
(r) and the intercept were obtained for a ﬁxed time ofon, log DA/Dt= log k- + n log C Correlation coeﬃcient (r)
524 + 0.6389 log C 0.9971
526 + 0.8835 log C 0.9997
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Figure 10 Absorbance–time curves for the reaction between
GMFX and KMnO4 in aqueous medium: 2.0 mL of 5 · 103 M
KMnO4 and GMFX (a) 4.10 · 105 (b) 5.13 · 105 (c)
6.15 · 105, (d) 7.18 · 105 and (e) 8.20 · 105 M.
0
0.2
0.4
0.6
0.8
1
1.2
0 5 10 15 20 25 30
Time, min
A
bs
or
ba
nc
e a
b
c
d
e
Figure 11 Absorbance–time curves for the reaction between
GTFX and KMnO4 in aqueous medium: 2.0 mL of 5 · 103 M
KMnO4 and GTFX: (a) 4.25 · 105, (b) 5.32 · 105 (c)
6.38 · 105, (d) 7.44 · 105 and (e) 8.51 · 105 M.
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interval for measurement. The analytical parameters for the
determination of drugs in pure form by the ﬁxed time methodTable 2 Regression equations for the studied drugs of different conc
Drug Time, min Regression e
GMFX 2 0.1296 + 0.0
5 0.2135 + 0.0
7 0.2583 + 0.0
10 0.3197 + 0.0
13 0.4259 + 0.0
15 0.4764 + 0.0
20 0.4992 + 0.0
25 0.5400 + 0.0
30 0.5612 + 0.0
2 0.0210 + 0
5 0.0058 + 0.0
7 0.0244 + 0.0
GTFX 10 0.0366 + 0.0
13 0.0590 + 0.0
15 0.0616 + 0.0
20 0.0697 + 0.0
25 0.0777 + .04
30 0.0928 + 0.0
* A is the absorbance at 610 nm and C is the concentration in lg mL1.are shown in Table 2. After optimizing the reaction conditions,
the ﬁxed time method was applied to the determination of the
studied drugs in pure form over the concentration range of 4–
36 and 4–40 lg mL1 for GMFX and GTFX, respectively.
3.2.2. Rate constant method
Graphs of log (absorbance) versus time for GMFX concentra-
tions in the range of 2.05 · 105–1.02 · 104 M and GTFX
concentrations in the range of 2.12 · 105–1.06 · 104 M were
plotted. Pseudo-ﬁrst-order rate constants (K) corresponding to
different concentrations of the investigated drugs [C] were cal-
culated from the slopes multiplied by 2.303 (Table 3).
Regression of K values versus [C] gave the equations:
K ¼ 0:0011þ 5:533C; r ¼ 0:9839 for GMFX
K ¼ 0:00085þ 4:739C; r ¼ 0:9821 for GTFX
where A is the absorbance at 604 nm and C is the molar con-
centration. The method suffered from poor linearity as indi-
cated from r value, therefore this method was excluded.
3.2.3. Fixed absorbance method
Reaction rates were determined for different concentrations of
the investigated drugs. A pre-selected absorbance value was
ﬁxed (0.5 for both GMFX and GTFX) for different concentra-
tions of the studied drugs, in the range of 2.05 · 105–
1.02 · 104 M for GMFX and 2.12 · 105 to 1.06 · 104 M
for GTFX and the time required for each concentration to
reach the preselected absorbance value was measured in sec-
onds. The reciprocal of time (1/t) versus drug concentrations
was plotted and the following equations were obtained by lin-
ear regression:
1=t ¼ 0:00057þ 162:28C; r ¼ 0:9960 for GMFX
1=t ¼ 0:0044þ 131:57C; r ¼ 0:9965 for GTFX
The concentration ranges giving the most satisfactory calibra-
tion graphs were limited, therefore this method was abandoned.entrations at different time intervals using the ﬁxed time method.
quation*A= a+ bC Correlation coeﬃcient (r)
322C 0.9984
3668C 0.9959
3803C 0.9954
4148C 0.9916
4173C 0.9993
4285C 0.9998
429C 0.9939
415C 0.9894
4083C 0.9865
.03195C 0.9995
3605C 0.9983
391C 0.9985
417C 0.9974
4325C 0.9987
456C 0.9991
4678C 0.9991
828C 0.9990
483C 0.9987
Table 3 Values of K calculated from slopes of log A versus t graphs multiplied by 2.303 for different concentrations of the studied
drugs.
Drug [Drug] K Regression equation Correlation coeﬃcient (r)
GMFX 2.05 · 105 9.442 · 104 K= 0.0011 + 5.533C 0.9839
4.10 · 105 8.728 · 104
6.15 · 105 6.701 · 104
8.20 · 105 6.125 · 104
1.02 · 104 5.066 · 104
2.12 · 105 7.622 · 104
4.25 · 105 6.310 · 104
GTFX 6.38 · 105 5.135 · 104 K= 0.00085 + 4.739C 0.9821
8.51 · 105 4.652 · 104
1.06 · 104 4.490 · 104
Table 4 Analytical parameters for the determination of
GMFX and GTFX in pure form using the ﬁxed time method.
Parameters GMFX GTFX
kmax, nm 610 610
Temperature, C 70 ± 2 50 ± 2
Heating time, min 15 15
Beer’s law limit, lg mL1 4–36 4–40
Molar absorptivity, L mol1 cm1 1.21 · 104 1.18 · 104
Sandell’s sensitivity, ng cm2 29.72 31.97
Correlation coeﬃcient (r) 0.9998 0.9991
Regression equation*
Slope (b) 0.0299 0.0312
Intercept (a) 0.2930 0.1482
Sy/x 8.36 · 103 1.85 · 103
SD of slope (Sb) 1.22 · 103 2.72 · 104
SD of intercept (Sa) 7.79 · 103 1.73 · 103
LOD, lg mL1 0.0778 0.0778
LOQ, lg mL1 0.2951 0.2591
* Regression equation: A= a+ bC, where C is the concentration
of drug (lg mL1).
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The kinetic curves obtained at different concentrations of
GMFX or GTFX, under the optimized conditions, wereTable 5 Intra- and inter-day precision and accuracy of the reaction o
method.
Frequency of analysis Drugs Taken, lg mL1 R
Intra GMFX 8 99
20 99
32 99
Enter 8 99
20 99
32 99
Intra GTFX 8 99
20 99
32 99
Enter 8 99
20 99
32 99
a Relative standard deviation for ﬁve determinations.
b Er, relative error.
c Standard error.processed by the ﬁxed-time method. Calibration graphs of
absorbance versus initial concentrations of GMFX or GTFX
were established at different ﬁxed-time intervals. It was found
that the slopes increase with time and the most acceptable val-
ues of the correlation coefﬁcient (r) and the intercept were ob-
tained at a ﬁxed time of 15 min for both GMFX and GTFX
which were, therefore, chosen as the most suitable time inter-
vals for measurement. The calibration graphs were linear over
the concentration range of 2.05 · 105–1.02 · 104 M for
GMFX and 2.12 · 105–1.06 · 104 M for GTFX. Regression
analysis indicates linear relationships with negligible inter-
cepts. Table 4 presents the analytical parameters, molar
absorptivity and the results of the statistical analysis of the
experimental data: regression equations calculated from cali-
bration graphs along with standard deviation of the slope
(Sb) and intercept (Sa) on the ordinate and the standard devi-
ation of residuals (Sy/x). The high values of the correlation
coefﬁcients of regression equations indicate good linearity
and conformity to Beer’s law.
3.4. Accuracy and precision
The accuracy and precision of the proposed kinetic spectro-
photometric method were determined in terms of intermediate
precision (intra-day and inter-day). Three different concentra-
tions of the studied drugs were analyzed in ﬁve replicates
during the same day (intra-day precision) and for seven con-f GMFX and GTFX by the proposed kinetic spectrophotometric
ecovery, % RSDa,% Erb% SEc
.691 1.295 6.0 · 103 3.316 · 103
.998 0.841 2.0 · 103 3.872 · 103
.999 0.461 2.0 · 103 2.549 · 103
.999 1.391 4.0 · 103 3.674 · 103
.999 0.491 3.0 · 103 2.236 · 103
.999 0.519 0.012 2.915 · 103
.999 0.634 4.4 · 103 1.224 · 103
.998 0.976 3.0 · 103 3.741 · 103
.999 0.118 2.2 · 103 6.244 · 103
.998 0.618 0.025 1.224 · 103
.999 0.405 4.0 · 103 1.581 · 103
.998 0.340 6.0 · 103 1.870 · 103
Table 6 Application of the proposed kinetic spectrophotometric method to the determination of GMFX and GTFX in dosage forms.
Drug Formulations Nominal value Recoverya, ±SD t-Test F-test Reported methods
GMFX Floxguardb 320 mg/tablet 99.996 ± 0.377 0.795 2.294 100.06 ± 0.571
GTFX Tymerc 3 mg/ml 99.996 ± 0.493 1.117 2.211 99.60 ± 0.733
The theoretical values of t and F at P= 0.05 are 2.31 and 6.39, respectively.
a Average of ﬁve determinations.
b Product of Al-Debeiky Pharma, Al-Obour City, Egypt.
c Product of JamJoom pharmaceuticals, Jaddah, Saudi Arabia.
spectrophotometric determination of GMFX and GTFX S65secutive days (inter-day precision). The analytical results ob-
tained from the investigation are summarized in Table 5.
The percentage relative standard deviation (RSD%) for the re-
sults did not exceed 1.4% (Table 5), proving the high
reproducibility of the results and the precision of the method.
This good level of precision was suitable for quality control
analysis of the studied drugs.
3.5. Analytical applications
The ﬁxed-time method has been successfully applied to deter-
mine GMFX in tablets and GTFX in eye drops. The concen-
trations of each drug were calculated using the corresponding
regression equations at ﬁxed time of 15 min for both GMFX
and GTFX. The results obtained are presented in Table 6. Sta-
tistical analysis of the results obtained by both the proposed
method and reported spectrophotometric methods, [11,12,36]
revealed no signiﬁcant difference in the performance of the
two methods regarding accuracy and precision as revealed by
t-test and F-test, respectively (Table 6).
4. Conclusion
The proposed method can be easily applied to the determina-
tion of GMFX and GTFX in pure and dosage forms, which do
not require elaborate treatment of the analyte and tedious
extraction of the chromospheres produced. The proposed
method (ﬁxed-time) is sensitive enough to enable determina-
tion of a lower amount of the drugs. These advantages encour-
age the application of the proposed method in routine quality
control of the investigated drugs in industrial laboratories. No
interference has been observed with excipients found in drug
formulations.
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